When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
Marianne Geleijnse, Vice President of the Dutch Health Council, discussed human health as a multidimensional concept. Dr Geleijnse along with Roel Vermeulen, Utrecht University, and Martine van der…
Brian Shuch, MD, director of the UCLA Kidney Cancer Program, discusses renal cysts. These are very common, especially in individuals over the age of 50, and are usually asymptomatic.…
Nephrologist Sumeska Thavarajah, MD, of Johns Hopkins, highlights that CKD is more common than realized, affecting about 37 million adults in the US, but 90% may not be…
Majd Isreb, MD, FACP, FASN, IFMCP, from the Integrative Kidney Institute, discusses the link between inflammation and chronic kidney disease (CKD). He explains that CKD patients have higher…
This webinar snippet features Neera Dahl, MD, PhD, professor of medicine, medical director of nephrology, and director of the Nephrology Clinical Trials Program at Yale School of Medicine,…
A Kishore Kumar, MD, DM, a consultant nephrologist and renal transplant physician at PACE Hospitals, discusses high blood potassium levels in patients with kidney disease. For patients with…
